Kairos Pharma, LTD. (KAPA): auditor change — Kairos Pharma replaces auditor Marcum with Weinberg; 2023 report had going concern

Kairos Pharma, LTD.

Audit committee dismissed Marcum LLP and appointed Weinberg & Company effective April 23, 2025.
Marcum's 2023 audit report included a going concern uncertainty; 2024 report had no such modification.
No disagreements on accounting principles or audit scope occurred during Marcum's tenure.
Material weaknesses in internal control over financial reporting were disclosed for 2024 and 2023.
Marcum provided a letter agreeing with the statements in this 8-K filed as Exhibit 16.1.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Kairos Pharma, LTD. engaged Weinberg and Company, P.A. as its auditor.

Action: engagement
Auditor: Weinberg and Company, P.A.

Exact text from the filing

On April 23, 2025, the audit committee of Kairos Pharma, Ltd. (the “Company”) selected Weinberg and Company, P.A. (“Weinberg”) to serve as the Company’s independent registered public accounting firm for the review of its Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ending December 31, 2025.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Kairos Pharma, LTD. dismissed Marcum LLP as its auditor.

Action: dismissal
Auditor: Marcum LLP
Successor: Weinberg and Company, P.A.

Exact text from the filing

On April 23, 2025, the audit committee of Kairos Pharma, Ltd. (the “Company”) selected Weinberg and Company, P.A. (“Weinberg”) to serve as the Company’s independent registered public accounting firm for the review of its Quarterly Reports on Form 10-Q and Annual Report on Form 10-K for the fiscal year ending December 31, 2025. As a result, the audit committee dismissed Marcum LLP (“Marcum”) and Marcum would no longer serve as the Company’s independent registered public accounting firm, effective as of April 23, 2025.

View on SEC.gov

Browse all auditor changes →

Kairos Pharma, LTD. filing history →

Source: SEC EDGAR

accession 0001641172-25-006504

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.